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Abstract. We presented the first example of Cerenkov
luminescence imaging (CLI) and radioluminescence imag-
ing (RLI) of human tumor specimens. A patient with a
brain meningioma localized in the left parietal region was
injected with 166 MBq of 90Y-DOTATOC the day before
neurosurgery. The specimens of the tumor removed dur-
ing surgery were imaged using both CLI and RLI using
an optical imager prototype developed in our laboratory.
The system is based on a cooled electron multiplied
charge coupled device coupled with an f∕0.95 17-mm
C-mount lens. We showed for the first time the possibility
of obtaining CLI and RLI images of fresh human brain
tumor specimens removed during neurosurgery. © 2016
Society of Photo-Optical Instrumentation Engineers (SPIE) [DOI: 10.1117/1.
JBO.21.5.050502]
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Cerenkov luminescence imaging (CLI) and radioluminescence
imaging (RLI) are becoming well-established methods for
preclinical in vivo small animal optical imaging, as described
in recent reviews.1–3 CLI and RLI are based, respectively, on
the detection of Cerenkov radiation or scintillation light in
the visible range. CLI was mainly applied to image the biodis-
tribution of radiopharmaceuticals labeled with beta plus4–6 and
beta minus7,8 emitters. RLI was developed to obtain the biodis-
tribution of alpha9 and gamma emitters10 and can also be used in
combination with CLI to enhance the light output.11
Recent examples of CLI applications to humans were pre-
sented in Refs. 12 and 13. In Ref. 12, Cerenkov radiation from
the thyroid of a patient treated with 131I for hyperthyroidism
was imaged, while Ref. 13 presented an endoscopic Cerenkov
luminescence imaging approach to detect gastric cancers in
patients injected with 2-[18F]fluoro-2-deoxy-D-glucose.
In this work, we present an application of CLI and RLI for
the analysis of ex vivo fresh tumor specimens removed during
neurosurgery. The main goal of such an approach is to provide a
fast molecular imaging estimation of tumor uptake (almost in
real time) during surgical procedures. CLI and RLI images
were obtained by placing the tumor specimens in an optical
imager prototype developed in our laboratory.14
The detector used in the prototype is a cooled (−80°C) elec-
tron multiplied charge coupled device (EMCCD; Andor iXon
Ultra) coupled with an f∕0.95 17-mm C-mount lens (Schneider
Optics). The EMCCD has a back-illuminated 512 × 512 sensor
with pixel size equal to 16 μm, resulting in a detector with total
dimensions equal to 8.2 × 8.2 mm2.
The smallest achievable field of view (FOV) is
∼6.1 × 6.1 cm2, resulting in an image pixel size of 120 μm.
To exclude ambient light, the system is mounted on a black
light-tight enclosure, in which an adjustable stage is placed
for positioning the specimen.
All the CLI and RLI images were acquired using binning = 2
and 5 min of exposure time. A photographic black-and-white
image (binning = 2 and exposure time = 0.01 s) was always
acquired before any emission image to provide a reference
for CLI and RLI. A color image of the sample was also acquired
using a conventional camera to show the amount of blood
present in the sample.
RLI data were acquired by placing a slab of 1-cm plastic
scintillator on top of the specimen. To avoid any contamination,
the scintillator was placed ∼1 mm from the sample. Considering
that the plastic scintillator slab is almost transparent, the col-
lected light is thus the sum of Cerenkov and scintillator light
produced in the slab. This acquisition scheme (CLIþ RLI)
was adopted mainly to maximize the light collected by the CCD.
A patient with a grade 1 brain meningioma localized in the left
parietal region was injected with 166 MBq of 90Y-DOTATOC
the day before surgery. The patient participated in an experimen-
tal protocol of a radioguided surgery technique for cerebral
tumors with the use of a beta minus radiation probe,15 which
uses 90Y-DOTATOC for diagnostic purposes—contrary to its
traditional use with therapeutical quantities for peptide receptor
radionuclide therapy. In the new technique in Ref. 15, the
90Y-DOTATOC injected activity is calculated based on a diag-
nostic positron emission tomography–computed tomography
(PET-CT) imaging with the analogue 68Ga-DOTATOC radio-
pharmaceutical that allows evaluation of the activity concen-
trations in tumors and thus can establish the activity to be
administered for detection with the beta minus probe. In our
case, the tumor to nontumor standard uptake value ratio was
∼25. The required 90Y-DOTATOC activities are of a few hun-
dreds of MBq (typically 185 MBq, 166 MBq in our patient), and
the ensuing tumor activity concentrations are also suitable for
the study of CLI and RLI.
As shown in Ref. 16, meningiomas express somatostatin
receptors; thus, the 68Ga-DOTATOC and 90Y-DOTATOC
uptake in the tumor is specific.
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Figure 1(a) shows the 68Ga-DOTATOC image of our patient,
acquired two weeks before surgery. This time is sufficient
to guarantee the absence of any interaction between the
two radiotracers. A similar time interval was previously consid-
ered in a study aimed at comparing the biodistribution of
90Y-DOTATOC in the same patients under two renal protection
conditions.17
68Ga and 90Y have very different physical half-lives, but the
labeling of the same peptide—leading to 68Ga-DOTATOC and
90Y-DOTATOC—allows us to assume similar, if not identical,
kinetic processes in tumors and normal organs as well, as applies
for 111In-DOTATOC used as a surrogate for 90Y-DOTATOC, as
sustained by the joint IAEA, EANM, and SNMMI practical
guidance on peptide receptor radionuclide therapy (PRRT).18
The use of 68Ga-DOTATOC to foresee the outcome of therapy
with 177Lu- or 90Y-DOTATOC has been ascertained in the com-
munity of PRRT and has been discussed in several papers.19–22
Moreover, in the protocol of Ref. 15, the presumed activity of
90Y derived from the 68Ga estimates has also been compared
with the Monte Carlo simulations of the beta probe sensitivity,
showing results in good agreement (data not shown from a paper
submitted by Solfaroli Camillocci et al.).
The diagnostic T2 magnetic resonance images of the patient
acquired without contrast medium before surgery are shown in
Fig. 1(b). The study was approved by the ethical committee of
the Carlo Besta Neurological Institute, and informed consent
was signed by the patient.
The tumor diameter was ∼3.5 cm and the volume was
∼18 cm3. From the DOTATOC uptake derived from PET images,
we could estimate the activity concentration of 90Y-DOTATOC
in the tumor during surgery to be equal to 4.8 kBq∕ml.
90Y (T1∕2 ¼ 2.66 days) decays mainly by beta minus emis-
sion with end point energy equal to 2.28 MeV and a small frac-
tion of pair production. Because of the direct interaction with the
CCD of bremsstrahlung and gamma rays emitted by 90Y, a small
sparse spike noise pattern is generated during the emission
image acquisition. The spikes have been removed by applying
a box median filter with a size equal to 3 × 3 pixels on the emis-
sion data.
The specimens of the tumor removed by the surgeon were
imaged using both CLI and RLI as described before. The sample
activity could not be directly measured simply because surgery
was carried out in a hospital that did not have a nuclear medicine
division with appropriate instrumentation. The sample has a
dimension of 5 × 11 × 9 mm3; thus, the estimated activity was
equal to 2.4 kBq.
Figure 2(a) shows the photographic picture of the tumor
specimen, Fig. 2(b) the Cerenkov image, and Fig. 2(c) the RLI
signal. The images confirm an appropriate localization of the
visible Cerenkov and radioluminescence light signal within the
tumor region.
To our knowledge, this is the first published experimental
evidence of the possibility of detecting Cerenkov and radiolu-
minescence light from a fresh human tumor specimen removed
during surgery.
As expected, the detected light signal is higher in RLI with
respect to CLI; we used the same color scale in order to provide
a better comparison between CLI and RLI signals. A circular
(3 mm diameter) region of interest was drawn at the center
of the tumor specimen, and the mean value was calculated for
both CLI and RLI. We found that the average values of the CLI
and RLI signal were, respectively, equal to 582 and 652 (arbi-
trary units).
The higher background signal in RLI data around the speci-
men is due to direct interaction of the high-energy beta particles
with the scintillator slab.
In summary, we showed, for the first time, examples of CLI
and RLI images of a fresh human brain tumor specimen removed
during neurosurgery of a patient previously administered, for
investigational purposes, with 166 MBq of 90Y-DOTATOC.
The FOV of 6.1 × 6.1 cm allows the acquisition of few sur-
gical samples simultaneously, reducing the total time needed for
the imaging process.
As shown by recent Monte Carlo simulation,23 the use of 90Y
is ideal considering the higher number of Cerenkov photons
emitted in the tissues with respect, for example, to 18F.
The CLI signal of the specimen is well confined in the tumor
region, while the RLI signal is higher but also contains higher
Fig. 1 (a) The coronal, sagittal, and axial PET-CT images of the patient injected with 68Ga-DOTATOC.
The PET images were used to estimate the activity concentration of 90Y-DOTATOC in the tumor during
surgery. (b) The T2 MR images of the patient acquired without contrast medium.
Journal of Biomedical Optics 050502-2 May 2016 • Vol. 21(5)
JBO Letters
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 10 Dec 2019
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
background outside the sample. We can conclude that CLI is the
best option when the Cerenkov signal is high enough to be
clearly detected, while RLI can be a good alternative option
when the Cerenkov light is low. More precisely, RLI can be
the best imaging approach when the radiotracer uptake is low,
when using isotopes with low Cerenkov light yield, or with end
point energy below the Cerenkov threshold.
The approach presented in this work could provide a fast
molecular imaging method for the estimation of tumor
radiopharmaceutical uptake during surgical procedures using
Cerenkov and radioluminescence light.
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